Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 extension study of UGN-101 for recurrent low-grade upper tract urothelial carcinoma after prior complete response
MOH_2019-07-01_007243Phase 3Completed
- Sponsor
- UroGen Pharma
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mitomycin c in upper tract urothelial carcinoma (UTUC), sponsored by UroGen Pharma. Primary endpoint: Efficacy and safety of UGN-101 in recurrent disease. Started Jul 2019; status: completed.
02
Drugs
mitomycin c
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on MOH_2019-07-01_007243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-01_007243.